Gene editing · Gene editing: glucose-6-phosphatase catalytic subunit 1 (G6Pase-α) (G6PC1) · developed by Beam Therapeutics
BEAM-301 is a base editing therapy designed to correct the G6PC1 c.247C>T variant through an A:T-to-G:C base-pair substitution, restoring G6Pase-α catalytic activity. It is being studied in glycogen storage disease type Ia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06735755 | Phase 1/2 | Glycogen Storage Disease Type Ia | Recruiting | BEAM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Glycogen Storage Disease Type Ia
Updated Oct 11, 2026. Something wrong or missing? Report it on the BEAM page.
See BEAM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BEAM catalysts and pipeline →